Calcitonin Gene Related Peptide (CGRP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

June 2022 | 79 pages | ID: C00F6EE81ED5EN
Global Markets Direct

Abstracts

Calcitonin Gene Related Peptide (CGRP) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Calcitonin Gene Related Peptide (CGRP) – Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exists in two forms alpha-CGRP and beta-CGRP. CGRP is produced in both peripheral and central neurons. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and contribute to the regeneration of nervous tissue after injury. CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and linked to the transmission of pain. CGRP also plays an important role in cardiovascular homeostasis and nociception.

Calcitonin Gene Related Peptide (CGRP) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Preclinical and Discovery stages are 1, 1, 1, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology and Oncology which include indications Migraine, Cluster Headache Syndrome (Cluster Headache), Dental Pain (Toothache/Tooth Pain), Inflammatory Pain, Medullary Thyroid Cancer, Osteoarthritis Pain and Psoriasis.

The latest report Calcitonin Gene Related Peptide – Drugs In Development, 2022, outlays comprehensive information on the Calcitonin Gene Related Peptide (CGRP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP) Calcitonin Gene Related Peptide (CGRP)
• The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects
• The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Calcitonin Gene Related Peptide (CGRP) – Overview
Calcitonin Gene Related Peptide (CGRP) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Calcitonin Gene Related Peptide (CGRP) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide (CGRP) – Companies Involved in Therapeutics Development
Acherx LLC
AfaSci Inc
Eli Lilly and Co
H. Lundbeck AS
Kissei Pharmaceutical Co Ltd
Nepsone ehf
Pharmnovo AB
Shandong Boan Biotechnology Co Ltd
Shanghai Junshi Bioscience Co Ltd
Teva Pharmaceutical Industries Ltd
Vaxxinity Inc
Calcitonin Gene Related Peptide (CGRP) – Drug Profiles
ACX-101 – Drug Profile
Product Description
Mechanism Of Action
History of Events
AFAP-3 – Drug Profile
Product Description
Mechanism Of Action
History of Events
eptinezumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
fremanezumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
galcanezumab – Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Inhibit CGRP for Medullary Thyroid Cancer – Drug Profile
Product Description
Mechanism Of Action
History of Events
JS-010 – Drug Profile
Product Description
Mechanism Of Action
KCZ-1279 – Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibody to Inhibit CGRP for Migraine – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit CGRP for Psoriasis – Drug Profile
Product Description
Mechanism Of Action
UB-313 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Calcitonin Gene Related Peptide (CGRP) – Dormant Products
Calcitonin Gene Related Peptide (CGRP) – Discontinued Products
Calcitonin Gene Related Peptide (CGRP) – Product Development Milestones
Featured News & Press Releases
Jun 24, 2022: Teva announces promising interim results from its study PEARL, about the impact of AJOVY (fremanezumab)
Jun 16, 2022: Results from the DELIVER study with Vyepti has been published in a top-ranking medical journal
Jun 15, 2022: Otsuka obtains approval in Japan for Auto-Injector dosage form for AJOVY subcutaneous injection 225 mg for preventive treatment of migraine
Jun 09, 2022: Lundbeck to present data on VYEPTI (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, furthering clinical and real-world evidence for migraine prevention
Jun 09, 2022: Teva to present latest data on AJOVY (fremanezumab-vfrm) injection at the 2022 American Headache Society Annual Meeting
Jun 09, 2022: New real-world data evaluating AJOVY (fremanezumab-vfrm) injection use in patients with migraine presented at 2022 American Headache Society Annual Meeting
May 17, 2022: Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s AJOVY (fremanezumab), for the preventive treatment of migraine in adults
Apr 02, 2022: Lundbeck to present new data at AAN 2022 adding to clinical evidence regarding VYEPTI
Apr 01, 2022: Teva to present new analyses of AJOVY (fremanezumab-vfrm) injection and AUSTEDO (deutetrabenazine) tablets at 2022 American Academy of Neurology Annual Meeting
Mar 02, 2022: Teva Canada welcomes public drug plan reimbursement by Alberta, Saskatchewan, Qu?bec, Veteran Affairs Canada and the Non-Insured Health Benefits Program for Patients prescribed AJOVY (fremanezumab) for the preventive treatment of migraine in adults
Jan 24, 2022: Vyepti (eptinezumab) approved by the EU Commission for the preventive treatment of migraine in adults
Nov 19, 2021: Lilly begins enrolment in Phase IV trial of Emgality for migraine prevention
Nov 12, 2021: Vyepti recommended for approval in the EU by CHMP for the preventive treatment of migraine in adults
Nov 08, 2021: From clinical trial efficacy to real-world effectiveness first AJOVY (fremanezumab) data from European Real World Evidence Program
Nov 01, 2021: Lundbeck reports positive results for Vyepti(eptinezumab) from the DELIVER study in patients with migraine and prior preventive treatment failures
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Acherx LLC, 2022
Pipeline by AfaSci Inc, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by H. Lundbeck AS, 2022
Pipeline by Kissei Pharmaceutical Co Ltd, 2022
Pipeline by Nepsone ehf, 2022
Pipeline by Pharmnovo AB, 2022
Pipeline by Shandong Boan Biotechnology Co Ltd, 2022
Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Pipeline by Teva Pharmaceutical Industries Ltd, 2022
Pipeline by Vaxxinity Inc, 2022
Dormant Projects, 2022
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022